EGFR TKI (1st generation) · small molecule
gefitinib
6 active trials across 2 of our biomarkers, targeting EGFR. 2 active approvals for a biomarker on marked.bio.
Also known as ZD1839, Iressa.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Approvals and pivotal results
Biomarker-selected approvals in the United States and the European Union, with the pivotal trial's results and side effects where we have them. Results from different trials are not directly comparable.
| Therapy | Biomarker | Tumour | United States | European Union |
|---|---|---|---|---|
gefitinib
|
EGFR exon 19 deletion / L858R | NSCLC | Approved 2015 | Approved 2009 |
In the US label
IFUM
single-arm, 106 patients Stopped for side effects about 5% Trial details and side effects
In the EU product information
IPASS (EGFR-mutation-positive subgroup)
vs carboplatin + paclitaxel, 261 (subgroup) Trial details and side effects
|
||||
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| EGFR exon 19 deletion / L858R | 6 | 87 | Phase 3 |
| EGFR exon 20 insertion | 0 | 1 | – |
Sponsors
Industry sponsors leading active biomarker-selected trials of gefitinib.
- Allist Pharmaceuticals 1
- Eli Lilly 1
- Novartis 1
Trials
6 of 87 trials shown
-
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
furmonertinibgefitinib FDA EU
…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).
EGFR exon 19 deletion / L858RLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
-
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
ramucirumab FDA EUerlotinib FDA EUgefitinib FDA EUosimertinib FDA EU
…h erlotinib based on documented evidence of tumor harboring an activating EGFR mutation \[exon 19 deletion or exon 21 (L858R) substitution mutation\].
EGFR exon 19 deletion / L858RMetastatic Non-Small Cell Lung Cancer
-
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
gefitinib FDA EUerlotinib FDA EUafatinib FDA EUosimertinib FDA EU
Positive EGFR mutations are diagenesis.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
-
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
gefitinib FDA EUosimertinib FDA EU
…e histologically confirmed stage IV NSCLC (per AJCC 7th edition) with either the L858R or exon 19 deletion activating EGFR mutation as identified in a CLIA-approved laboratory.
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
nazartinibtrametinibribociclibnaporafenibcapmatinibgefitinib FDA EU
…tologically confirmed locally advanced (stage IIIB) or metastatic (stage IV) EGFR mutant (ex19del, L858R) NSCLC.
EGFR exon 19 deletion / L858REGFR-mutant Non-small Cell Lung Cancer
-
Therapy for Advanced NSCLC With EGFR 19delins Mutation
icotinibgefitinib FDA EUbefotertinibosimertinib FDA EUfurmonertinib
Epidermal growth factor receptor (EGFR) exon 19 deletion-insertion mutation (19delins) documented by testing of tumor tissue or plasma samples usi…
EGFR exon 19 deletion / L858RLung Cancer
-
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
Elemene plus first or third generation EGFR-TKIsgefitinib FDA EUerlotinib FDA EUicotinibosimertinib FDA EUaumolertinibfurmonertinib
Patients with EGFR mutations (deletions in exon 19 and L858R in exon 21 of the EGFR gene), plan to receive First-generation EGFR-TKIs (Gefit…
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma
-
Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
gefitinib FDA EUgemcitabinecarboplatin
Harboring activating mutation of EGFR,only including an exon 19 deletion or an exon 21 point mutation.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer Metastatic, EGFR Activating Mutation
-
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
erlotinib FDA EUgefitinib FDA EUicotinibdocetaxelpemetrexedcisplatincarboplatin
EGFR mutation-positive (EGFR exon-18, exon-19 or exon-21);
EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer
-
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
gefitinib FDA EU
…c non-small cell lung cancer (i.e. cancer that has spread from where it started) which is EGFR mutation positive
EGFR exon 19 deletion / L858RCaucasian Patients With EGFR Mutation Positive Advanced NSCLC
-
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
gefitinib FDA EU
Patient who can provide sample for EGFR mutation test
EGFR exon 19 deletion / L858RNon Small Cell Lung Carcinoma
-
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
rezivertinibgefitinib FDA EU
…rollment, a central laboratory testing report has confirmed that the tumor has one of two common EGFR mutations positive that are sensitive to EGFR-TKI therapy, accompanied with or not accompanied with…
EGFR exon 19 deletion / L858REGFR exon 20 insertionNSCLC
-
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
lazertinib FDA EUgefitinib FDA EU
… least 1 of the 2 common EGFR mutations known to be associated with EGFR TKI sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
SH-1028 tabletsgefitinib FDA EU
…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either or in combination with other EGFR mutations assessed by central testing u…
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
Abivertinib Maleate Capsulesgefitinib FDA EU
…umor tissue or cytopathological specimens have any of two common sensitive EGFR mutation (Ex19del or L858R) as confirmed by tests with Cobas (Roche) kit in central lab of this study, whic…
EGFR exon 19 deletion / L858RAdvanced Non-small Cell Lung Cancer
-
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
limertinibgefitinib FDA EU
…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R) that have been confirmed by the central laboratory testing report before enrollme…
EGFR exon 19 deletion / L858RLocally Advanced or Metastatic NSCLC
-
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
5.Documented evidence of tumor harboring an activating EGFR mutation (exon19 del and L858R)
EGFR exon 19 deletion / L858RLung Cancer, Nonsmall Cell
-
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
aumolertinibgefitinib FDA EU
…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either or in combination with other EGFR mutations assessed by central testing u…
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
nazartiniberlotinib FDA EUgefitinib FDA EU
…ic, stage IIIB/ IIIC or stage IV NSCLC with documented EGFR activating mutation (L858R or ex19del)
EGFR exon 19 deletion / L858RCarcinoma, Non-small Cell Lung
-
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
AZD3759erlotinib FDA EUgefitinib FDA EU
Histologically or cytologically confirmed diagnosis of NSCLC with activating EGFR mutations including L858R and/or Exon19Del.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases
-
To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma
gefitinib FDA EUvinorelbinecarboplatin
The gene detects EGFR mutations is positive;
EGFR exon 19 deletion / L858RNSCLC, EGFR
-
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
naquotinib mesilateerlotinib FDA EUgefitinib FDA EU
Subject has an EGFR activating mutation (exon 19 deletion or exon 21 L858R), with or without T790M mutation, by local or central testing on examina…
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer (NSCLC)
-
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Documented evidence of tumor harboring an activating EGFR mutation (Example 19 del and L858R) .
EGFR exon 19 deletion / L858REGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors
-
Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma
gefitinib FDA EUYiqi-yangyin-jiedu decoction
With activating EGFR mutation (either exon19del or exon21L858R) and one month of gefitinib as first-line or second-line therapy without d…
EGFR exon 19 deletion / L858RCancer
-
Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer
gefitinib FDA EUpemetrexed
Patient who was confirmed stage IV NSCLC with EGFR activating mutation and brain metastases by pathologic histology or cytology
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, Brain Metastases, EGFR Mutation
-
EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
gefitinib FDA EUpemetrexedgemcitabinecarboplatin
EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer
-
Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma
gefitinib FDA EUpemetrexed
…arget population is completely resected pathological stage II-IIIA(N1-N2) NSCLC with EGFR exon 19 deletions and exon 21 L858R activating mutation.
EGFR exon 19 deletion / L858RLung Neoplasms
-
Gefitinib Combined With Thalidomide to Treat NSCLC
Thalidomidegefitinib FDA EUaspirin
The NSCLC harbors EGFR-mutation and are previously untreated
EGFR exon 19 deletion / L858RNSCLC
-
Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)
gefitinib FDA EUerlotinib FDA EUicotinib
Positive EGFR mutation.
EGFR exon 19 deletion / L858RStage IV EGFR Mutated NSCL With Brain Metastases
-
EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC
gefitinib FDA EUerlotinib FDA EUicotinib
… who was confirmed non-small cell lung cancer (NSCLC) by histology or cytology, harboring EGFR mutant type (19 and/or 21 exon mutation).
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB
gefitinib FDA EUdocetaxelcisplatin
…d by Taxane Platinum Chemotherapy and Intercalated Gefitinib in NSCLC Stages II-IIIB With Activating EGFR Mutation - A Single Arm Phase II Trial.
EGFR exon 19 deletion / L858RNon-squamous Non-small Cell Lung Cancer Stage II, Non-squamous Non-small Cell Lung Cancer Stage IIIA, Non-squamous Non-small Cell Lung Cancer Stage IIIB, Activating EGFR Mutation
-
Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
gefitinib FDA EU
Sequencing EGFR mutation(primary lesion or metastases,exon 19 deletions or exon 21 L858R (EGFR mutation in exon 21, L858R point mutation) mutations;
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation
-
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
osimertinib FDA EUerlotinib FDA EUgefitinib FDA EU
…ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).
EGFR exon 19 deletion / L858RLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
-
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
dacomitinib FDA EUgefitinib FDA EU
…med, advanced NSCLC (with known histology) with the presence of EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21).
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer With EGFR-Activating Mutations
-
A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone
gefitinib FDA EUpemetrexedcisplatin
…otherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Have Progr…
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation
gefitinib FDA EUvinorelbinecisplatin
…arget population is completely resected pathological stage II-IIIA(N1-N2) NSCLC with EGFR exon 19 deletions and exon 21 L858R activating mutation.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
erlotinib FDA EUgefitinib FDA EU
EGFR mutation (exon 19 or 21)
EGFR exon 19 deletion / L858RLung Cancer
-
Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib
Histologically confirmed that EGFR sensitive mutation (ex19del or L858R mutation) in tumor tissue was detected by non-squamous NSCLC, and EGFR mutation …
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer, EGFR Gene Mutation
-
Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation
gefitinib FDA EUBerberine
Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)
EGFR exon 19 deletion / L858RLung Adenocarcinoma, EGFR Mutation
-
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
gefitinib FDA EU
4. exon 19 deletion or exon 21 L858R for EGFR mutation.
EGFR exon 19 deletion / L858RAdvanced NSCLC With EGFR Mutation
-
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
EGFR mutation (exon 19 deletion or exon 21 L858R) with Bim deletion or low abundance for EGFR mutation.
EGFR exon 19 deletion / L858RNon-small-cell Lung Cancer
-
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
nazartinibgefitinib FDA EU
An EGFR sensitizing mutation must be detected in tumor tissue.
EGFR exon 19 deletion / L858RLung Cancer
-
A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy
gefitinib FDA EUerlotinib FDA EUicotinib
…wly diagnosed metastatic lung adenocarcinoma harboring sensitizing EGFR mutations (L858R, exon 19 deletion), and became oligometastatic disease after 3 months TKI, evaluated by PET/CT scan, brain …
EGFR exon 19 deletion / L858RLung Adenocarcinoma, EGFR Positive Non-small Cell Lung Cancer
-
Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
gefitinib FDA EUpemetrexedgemcitabinecarboplatinbevacizumab
EGFR exon 19 deletion or exon 21 L858R.
EGFR exon 19 deletion / L858RNon-small-cell Lung Cancer
-
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
gefitinib FDA EUerlotinib FDA EUicotinibThymosin Alpha 1
…wly diagnosed metastatic lung adenocarcinoma harboring sensitizing EGFR mutations (L858R, exon 19 deletion), and showed stable disease after 3 months TKI, evaluated twice by PET/CT scan, brain MRI…
EGFR exon 19 deletion / L858RLung Adenocarcinoma
-
Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial
pemetrexedcarboplatingefitinib FDA EU
Sensitive EGFR mutations (19del, 21L858R);
EGFR exon 19 deletion / L858RLung Adenocarcinoma
-
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
fruquintinibgefitinib FDA EU
…-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring Activating EGFR Mutations : a Single-arm, Multicenter, Phase II Study
EGFR exon 19 deletion / L858RNSCLC
-
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
CT053PTSAgefitinib FDA EU
Histological or cytological evidence of EGFR mutation and T790M negative after progression on last EGFR TKI therapy
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
Thymalfasin (Thymosin alpha 1, Ta1)afatinib FDA EUgefitinib FDA EUerlotinib FDA EU
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
EGFR exon 19 deletion / L858REGFR Mutation Positive Non Small Cell Lung Cancer
-
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
gefitinib FDA EUpemetrexedgemcitabinecarboplatin
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
EGFR exon 19 deletion / L858RNonsmall Cell Lung Cancer, EGFR Gene Mutation
-
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
gefitinib FDA EU
All patients must have histologically proven NSCLC, with known EGFR mutation
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation
gefitinib FDA EU
Histologically confirmed stage IIIB/IV or recurrent NSCLC with activating EGFR mutation in exon 18 through exon 21 except T790M
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Third-line Treatment of Gefitinib in NSCLC Patients
gefitinib FDA EU
EGFR exon 19 deletion or exon 21 L858R substitution mutation confirmed;
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients
gefitinib FDA EU
Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients
EGFR exon 19 deletion / L858RLung Cancer
-
Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)
gefitinib FDA EU
Pathologically confirmed non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858 mutation.
EGFR exon 19 deletion / L858RNon-small-cell Lung Cancer
-
Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
erlotinib FDA EUgefitinib FDA EU
Harboring a PCR-confirmed activating mutation of EGFR, including an exon 19 deletion or an exon 21 L858R point mutation.
EGFR exon 19 deletion / L858RAdvanced Stage Non Small Cell Lung Cancer
-
Combination of Metformin With Gefitinib to Treat NSCLC
gefitinib FDA EUmetformin
…istologically or cytologically confirmed non small cell carcinoma of the lung who harbors EGFR-mutation and are previously untreated
EGFR exon 19 deletion / L858RNSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC
-
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
tepotinibgefitinib FDA EUpemetrexedcisplatincarboplatin
…e Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-TKI Therapy (INSIGHT)
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
gefitinib FDA EUfulvestranterlotinib FDA EU
The presence of analysable tissue for the research of EGFR activating mutation.
EGFR exon 19 deletion / L858RStage IV Lung Cancer
-
GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
vinorelbinegefitinib FDA EU
Evidence of activating mutations of EGFR
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
capmatinibgefitinib FDA EU
Documented EGFR mutation
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
gefitinib FDA EUpemetrexed
…st Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
EGFR exon 19 deletion / L858RCarcinoma, Non Small Cell Lung
-
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
gefitinib FDA EU
…s 3rd Line Treatment Re-challenge in Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Who Respon…
EGFR exon 19 deletion / L858RLung Cancer
-
Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone
…sessment: to be included in the study patients should present at least one EGFR mutation (exon 19 deletion or L858R with or without T790M).
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
afatinib FDA EUgefitinib FDA EU
Documented activating epidermal growth factor receptor mutation (Del19 and/or L858R) with tumour tissues.
EGFR exon 19 deletion / L858RLung Neoplasms
-
Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
gefitinib FDA EU
NSCLC with an activating sensitizing EGFR mutation
EGFR exon 19 deletion / L858RSquamous Cell Carcinoma of Bronchus
-
Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
gefitinib FDA EU
EGFR mutations (in exon 18, 19, or 21)
EGFR exon 19 deletion / L858RLung Cancer
-
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
gefitinib FDA EU
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
EGFR exon 19 deletion / L858RPulmonary Cancer
-
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
gefitinib FDA EUerlotinib FDA EUafatinib FDA EUosimertinib FDA EU
EGFR sensitizing mutation must be detected in tumor tissue.
EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer
-
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
DS-1205cgefitinib FDA EU
…rbors an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) OR
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC
gefitinib FDA EUerlotinib FDA EU
Newly diagnosed or patients on treatment for histologically confirmed advanced EGFR-mutant NSCLC defined as unresectable stage 3A, stage 3B or stage 4.
EGFR exon 19 deletion / L858RLung Cancer
-
A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
savolitinibgefitinib FDA EU
…e harbouring an EGFR mutation known to be associated with EGFR-TKI sensitivity (including exon 19 deletion, L858R, L861Q, G719X).
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer
gefitinib FDA EU
EGFR mutations (deletion of exon 19 and L858R mutation of exon 21) for which the clinical benefits of an EGFR-TKI (gefitinib …
EGFR exon 19 deletion / L858RNon-Small-Cell Lung Carcinoma
-
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients
gefitinib FDA EUtremelimumab
…tivating EGFR TK mutations known to be associated with EGFR TKI sensitivity (i.e., G719X, exon 19 deletion, L858R, L861Q) as determined locally using a well-validated and robust methodology ;
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer
-
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
gefitinib FDA EUdurvalumab
…e, histologically or cytologically confirmed locally advanced or metastatic NSCLC that is EGFR mutation positive, naïve to EGFR TKI therapy, and sensitive to EGFR TKIs therapy
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
-
A Study of LY2875358 in Japanese Participants With Advanced Cancer
LY2875358erlotinib FDA EUgefitinib FDA EU
…istologic or cytologic diagnosis of advanced NSCLC with epidermal growth factor receptor (EGFR) activating mutation, Stage IV per the 7th edition of the AJCC Staging Criteria for NSCLC.
EGFR exon 19 deletion / L858RSolid Tumors, Lymphoma, Carcinoma, Non-Small-Cell Lung
-
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
gefitinib FDA EU
known somatic mutation of the EGFR tyrosine kinase
EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
-
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
anlotinibgefitinib FDA EUicotinib
Previously, EGFR gene test showed EGFR exon 19 deletion or exon 21 (L858R) mutation, and the gene test showed no T790M mutation before enrollment…
EGFR exon 19 deletion / L858RNon-Small-Cell Lung
-
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
anlotinibgefitinib FDA EUerlotinib FDA EUicotinib
The patients should be confirmed with EGFR mutation \[e.g., T 790 M , exon 19 deletion, L 858 R, etc\],
EGFR exon 19 deletion / L858RNSCLC
-
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
gefitinib FDA EU
Target population is completely resected pathological stage IIIA-N2 NSCLC with EGFR exon 19 deletions and exon 21 L858R activating mutation.
EGFR exon 19 deletion / L858RLung Cancer
-
Phase I Study of the Combination of Anlotinib With Gefitinib
…rmed by molecular detection (including, but not limited to, 20 exon, 19 exon deletion and L858R) external pathological examination was accepted (including pathological or blood test res…
EGFR exon 19 deletion / L858RNon-squamous Non-small Cell Lung Cancer
-
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma
metforminerlotinib FDA EUafatinib FDA EUgefitinib FDA EU
NSCLC EGFR mutation-positive
EGFR exon 19 deletion / L858RNon-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation, EGFR Gene Mutation
-
Blood Detection of EGFR Mutation For Iressa Treatment
gefitinib FDA EU
EGFR sensitive mutation (including exon 19 del and/or exon 21 L858R) in plasma cf-DNA by ddPCR.
EGFR exon 19 deletion / L858RLung Adenocarcinoma
-
Combination of Chemotherapy and Gefitinib as First-line Treatment
pemetrexedcarboplatingefitinib FDA EU
…tinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial
EGFR exon 19 deletion / L858RNon-Small-Cell Lung Cancer
-
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
gefitinib FDA EUerlotinib FDA EUafatinib FDA EU
Patients with tumors harboring EGFR mutation (del 19 or L858R mutation) 6.
EGFR exon 19 deletion / L858REGFR Mutation Positive Non-small Cell Lung Cancer
-
Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis
gefitinib FDA EU
Activating mutation of EGFR
EGFR exon 19 deletion / L858REGFR-mutated Lung Adenocarcinoma, Brain Metastasis
-
Bone Metastasis on the Survival of Gefitinib Effective Patients
gefitinib FDA EU
4. whether patient was detected for EGFR gene mutation was not restricted.
EGFR exon 19 deletion / L858ROveral Survival, Non-small Cell Lung Cancer
No trials match these filters.